UNSPSC 51111905: Porfimer sodium

This classification denotes a photosensitizing agent with the molecular formula (C34H35N4NaO5)n.(C34H33N4NaO4)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y3834SIK5F, chemically known as 21h,23h-porphine-2,18-dipropanoic acid, 7-(1-(1-(8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21h,23h-porphin-2-yl)ethoxy)ethyl)-12-(1-hydroxyethyl)-3,8,13,17-tetramethyl- but generally known as porfimer sodium, which bears US NIH Compound Identifier 57166.

UNSPSC 51111905 Porfimer sodium, a Commodity code, covers a photosensitizing agent used in photodynamic therapy for treating certain cancers and precancerous conditions. State and local governments purchase this pharmaceutical primarily through health departments, hospital systems, and public medical centers that operate oncology and specialized treatment programs. The drug is dispensed as part of inpatient or outpatient cancer care protocols where it is activated by light exposure to destroy targeted malignant tissue. Procurement typically occurs through standing pharmaceutical supply agreements, hospital group purchasing organizations, or direct purchases via IFB or RFQ tied to treatment protocols and patient volume forecasts.

The source provided contains no recent state and local contract opportunities tagged to this code. Without posted solicitations or awarded contracts, the geographic distribution and current issuing-body activity cannot be characterized. Porfimer sodium procurement, when it does occur at the state and local level, is driven by individual institution treatment volume and budgetary cycles rather than by coordinated multi-jurisdiction demand signals typical of higher-activity commodity codes. Firms pursuing sales to public health systems should track hospital system RFPs and pharmaceutical supply agreements through individual state health department procurement channels and direct outreach to oncology program administrators.